Tianjin Lisheng Pharmaceutical Co., Ltd. (002393) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Tianjin Lisheng Pharmaceutical Co., Ltd.

Why is Tianjin Lisheng Pharmaceutical Co., Ltd. ?

Poor Management Efficiency with a low ROCE of 1.82%

The company has been able to generate a Return on Capital Employed (avg) of 1.82% signifying low profitability per unit of total capital (equity and debt)

Poor long term growth as Net Sales has grown by an annual rate of -0.11% and Operating profit at -6.87% over the last 5 years

The company has declared Negative results for the last 4 consecutive quarters

INTEREST(HY) At CNY 1.55 MM has Grown at 93.25%
PRE-TAX PROFIT(Q) At CNY 28.97 MM has Fallen at -76.6%
NET PROFIT(Q) At CNY 25.44 MM has Fallen at -75.99%

With ROE of 8.56%, it has a attractive valuation with a 1.17 Price to Book Value

Over the past year, while the stock has generated a return of 20.54%, its profits have risen by 15.4% ; the PEG ratio of the company is 0.9
At the current price, the company has a high dividend yield of 1.1

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Tianjin Lisheng Pharmaceutical Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Tianjin Lisheng Pharmaceutical Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Tianjin Lisheng Pharmaceutical Co., Ltd.

20.54%

0.64

36.56%

China Shanghai Composite

13.33%

0.90

14.74%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-0.11%

EBIT Growth (5y)

-6.87%

EBIT to Interest (avg)

34.34

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.43

Sales to Capital Employed (avg)

0.25

Tax Ratio

14.16%

Dividend Payout Ratio

48.50%

Pledged Shares

Institutional Holding

ROCE (avg)

1.82%

ROE (avg)

3.32%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.17

EV to EBIT

96.31

EV to EBITDA

31.37

EV to Capital Employed

1.29

EV to Sales

2.91

PEG Ratio

0.91

Dividend Yield

1.10%

ROCE (Latest)

1.34%

ROE (Latest)

8.56%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Bearish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

13What is working for the Company

NET PROFIT(HY)

Higher at CNY 314.12 MM

DIVIDEND PAYOUT RATIO(Y)

Highest at 276.24%

RAW MATERIAL COST(Y)

Fallen by -10.54% (YoY

DIVIDEND PER SHARE(HY)

Highest at CNY 2.37

-19What is not working for the Company

INTEREST(HY)

At CNY 1.55 MM has Grown at 93.25%

PRE-TAX PROFIT(Q)

At CNY 28.97 MM has Fallen at -76.6%

NET PROFIT(Q)

At CNY 25.44 MM has Fallen at -75.99%

OPERATING CASH FLOW(Y)

Lowest at CNY 136.33 MM

NET SALES(Q)

At CNY 275.77 MM has Fallen at -15.56%

DEBT-EQUITY RATIO (HY)

Highest at -39.5 %

Here's what is working for Tianjin Lisheng Pharmaceutical Co., Ltd.

Dividend per share

Highest at CNY 2.37

in the last five years

MOJO Watch

Company is distributing higher dividend from profits generated

DPS (CNY)

Dividend Payout Ratio

Highest at 276.24%

in the last five years

MOJO Watch

Company is distributing higher proportion of profits generated as dividend

DPR (%)

Raw Material Cost

Fallen by -10.54% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Tianjin Lisheng Pharmaceutical Co., Ltd.

Interest

At CNY 1.55 MM has Grown at 93.25%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Pre-Tax Profit

At CNY 28.97 MM has Fallen at -76.6%

over average net sales of the previous four periods of CNY 123.79 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (CNY MM)

Net Profit

At CNY 25.44 MM has Fallen at -75.99%

over average net sales of the previous four periods of CNY 105.94 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (CNY MM)

Net Sales

At CNY 275.77 MM has Fallen at -15.56%

over average net sales of the previous four periods of CNY 326.59 MM

MOJO Watch

Near term sales trend is very negative

Net Sales (CNY MM)

Operating Cash Flow

Lowest at CNY 136.33 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Debt-Equity Ratio

Highest at -39.5 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio